How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

561 results for

Interview Questions for the Physician Candidate


Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Sorafenib (Nexavar) for Metastatic Progressive Differentiated Thyroid Carcinoma

Context for the Clinical Guidance 4 2.2 Interpretation and Guidance 6 2.3 Conclusions 8 3 BACKGROUND CLINICAL INFORMATION 9 4 SUMMARY OF PATIENT ADVOCACY GROUP INPUT 11 5 SUMMARY OF PROVINCIAL ADVISORY GROUP (PAG) INPUT 15 6 SYSTEMATIC REVIEW 17 6.1 Objectives 17 6.2 Methods 17 6.3 Results 20 6.4 Ongoing Trials 36 7 SUPPLEMENTAL QUESTIONS 37 8 ABOUT THIS DOCUMENT 38 APPENDIX A: LITERATURE SEARCH STRATEGY 39 REFERENCES 41 pCODR Initial Clinical Guidance Report – Sorafenib (Nexavar) for Differentiated (...) with it. Therapeutic options for this patient population are limited, as radioiodine therapy cannot be administered in the setting of an intact thyroid gland. Patients who are not candidates for surgery or who refuse the disfiguring surgery that may be required are candidates for external beam radiation therapy to their thyroid gland but otherwise therapeutic options are extremely limited for these patients. The inability to safely give radioiodine therapy eliminates the most effective treatment option from

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

162. Public Health Interventions to Reduce the Secondary Spread of Measles

randomized controlled trial RR relative risk SAR secondary attack rate VE vaccine effectiveness Public Health Interventions to Reduce the Secondary Spread of Measles iii TABLE OF CONTENTS ACRONYMS AND ABBREVIATIONS ii EXECUTIVE SUMMARY 1 1. CONTEXT AND POLICY ISSUES 3 2. RESEARCH QUESTIONS 4 3. KEY FINDINGS 4 4. METHODS 5 4.1 Literature Search Strategy 5 4.2 Selection Criteria and Methods 5 4.3 Exclusion Criteria 6 4.4 Data Extraction Strategy 7 4.5 Critical Appraisal of Individual Studies 7 4.6 Subgroup (...) by systematically reviewing the clinical evidence on the effectiveness of these five public health interventions in reducing the secondary spread of measles during an outbreak in a population similar to Canada that has achieved elimination of endemic measles. Research Questions 1. What is the effectiveness associated with delivery of measles vaccine to susceptible measles contacts? 2. What is the effectiveness associated with immunoglobulin delivery to susceptible measles contacts? 3. What is the effectiveness

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

163. Regorafenib (Stivarga) Resubmission for mCRC

2.1.5 Summary of Supplemental Questions 7 2.1.6 Other Considerations 7 2.2 Interpretation and Guidance 9 2.3 Conclusions 10 3 BACKGROUND CLINICAL INFORMATION 12 4 SUMMARY OF PATIENT ADVOCACY GROUP INPUT 15 5 SUMMARY OF PROVINCIAL ADVISORY GROUP (PAG) INPUT 19 6 SYSTEMATIC REVIEW 20 6.1 Objectives 21 6.2 Methods 21 6.3 Results 23 6.4 Ongoing Trials 41 7 SUPPLEMENTAL QUESTIONS 42 8 ABOUT THIS DOCUMENT 43 APPENDIX A: LITERATURE SEARCH STRATEGY 44 REFERENCES 46 pCODR Initial Clinical Guidance Report (...) of patients diagnosed with CRC, both in terms of extending the probability of cure for patients with earlier-stage and resectable disease, and extending survival and QoL for patients living with mCRC. Patient advocacy group input based upon patient surveys and updated interviews with patients who have been on regorafenib therapy, highlights that prolonging PFS and allowing for extended control of their disease and improved QoL are important aspects when consideration is given to treatment. Patients

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

164. Bevacizumab (Avastin - with capecitabine) for Metastatic Colorectal Cancer

2.1.1 Introduction 4 2.1.2 Objectives and Scope of pCODR Review 5 2.1.3 Highlights of Evidence in the Systematic Review 5 2.1.4 Comparison with Other Literature 8 2.1.5 Summary of Supplemental Questions 8 2.1.6 Other Considerations 9 2.2 Interpretation and Guidance 9 2.3 Conclusions 11 3 BACKGROUND CLINICAL INFORMATION 12 4 SUMMARY OF PATIENT ADVOCACY GROUP INPUT 14 5 SUMMARY OF PROVINCIAL ADVISORY GROUP (PAG) INPUT 21 6 SYSTEMATIC REVIEW 23 6.1 Objectives 23 6.2 Methods 23 6.3 Results 26 6.4 (...) Ongoing Trials 39 7 SUPPLEMENTAL QUESTIONS 40 7.1 Bevacizumab in combination with 5-fluorouracil 40 7.2 Progression-free survival as a surrogate outcome for mCRC 45 8 ABOUT THIS DOCUMENT 50 APPENDIX A: LITERATURE SEARCH STRATEGY 51 REFERENCES 55 pCODR Initial Clinical Guidance Report - Bevacizumab (Avastin) and Capecitabine for Metastatic Colorectal Cancer pERC Meeting: June 18, 2015 ©2015 pCODR | PAN-CANADIAN ONCOLOGY DRUG REVIEW iv 1 GUIDANCE IN BRIEF 1.1 Background The purpose of this review

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

165. Hand Pain and Sensory Deficits: Carpal Tunnel Syndrome

comments, suggestions, and feedback gathered from public commentary were sent to the authors and editors to consider and make appropriate revisions in the guideline. In addition, a panel of consumer/patient representatives and external stakeholders, such as claims reviewers, medical cod- ing experts, academic educators, clinical educators, physician specialists, and researchers, also reviewed the guideline and provided feedback and recommendations that were given to the authors and editors for further (...) - scribed below. CLINICAL PRACTICE GUIDELINES Impairment/Function-Based Diagnosis PREVALENCE AND INCIDENCE I The overall lifetime prevalence of self-reported and physician-diagnosed carpal tunnel syndrome (CTS), regardless of work status, is 8.0%. 164 Prevalence in the United States working population, when confirmed by both electrodiagnostic testing and clinical examination, is 7.8%. 77 For women, the prevalence is nearly twice that for men (10% compared to 5.8%). There is a marked increase in preva

2019 The Orthopaedic Section of the American Physical Therapy Association (APTA), Inc.

166. Guidance on the clinical management of depressive and bipolar disorders, specifically focusing on diagnosis and treatment strategies

by psychiatrists, psychologists, physicians and others with an interest in mental health care. Conclusions: The Mood Disorder CPG is the first Clinical Practice Guideline to address both depressive and bipolar disorders. It provides up-to-date recommendations and guidance within an evidence-based framework, supplemented by expert clinical consensus. Mood Disorders Committee: Professor Gin Malhi (Chair), Professor Darryl Bassett, Professor Philip Boyce, Professor Richard Bryant, Professor Paul Fitzgerald, Dr (...) . The guideline is primarily directed at psychiatrists, psychologists and physicians with a particular interest in mental health issues. It will also be of benefit to other mental health care professionals, hospital administrators and government policy makers. It amalgamates evidence-based knowledge with clinical wisdom and makes recommendations for real-world practice. Structure. The Mood Disorders CPG comprises four sections: Section 1: Classification of mood disorders Section 2: Clinical management

2015 Royal Australian and New Zealand College of Psychiatrists

167. Planning, initiation & withdrawal of Renal Replacement Therapy

with one or two months pre-dialysis nephrology care was 1.23 whilst that for patients with no pre-dialysis nephrology care was 1.51(4). Now that most patients with advanced kidney failure, regardless of age and co-morbidity, are considered as potential candidates for RRT, the question of whether or not such treatment is the most appropriate option for the individual patient, has assumed increasing importance. Until recently, acceptance or non-acceptance for RRT in the UK was often determined by whether (...) or not a - 12 - patient was referred to a nephrology service. Effectively, decisions not to initiate RRT were taken by family members or referring physicians in isolation rather than in conjunction with the multidisciplinary nephrology team (8). It is often difficult to decide if patients with major co-morbidity will or will not benefit from starting dialysis, even if referred well in advance of the need for RRT, and there have been few studies of the decision not to start dialysis (9-11). Appropriate

2014 Renal Association

168. Patient Dignity (Formerly: Patient Modesty): Volume 95

think she would broach my privacy even if she was. I never heard her talk about patients and she struck me as being a true professional. The real issue for me was that the sisterhood in the neighborhood thought this was something they were entitled to given the opportunity they saw. Curiosity is a powerful incentive and so I don't doubt but that some healthcare staff let their curiosity override what they know is wrong. The Denver 5 anyone? A side question this prompts is does standard hospital (...) my voice and no longer being afraid of what they will think or say I am speaking up and demanding my privacy be respected. I am not a confrontational person by nature and do not look forward to conflict, but it is liberating to no longer be afraid and suffering their dehumanization in silence as a result. At , Anonymous said... Biker You don’t have to go very far to answer your question. “ Does standard hospital or medical practice protocol say that staff should not have people they know

2019 Bioethics Discussion Blog

169. For residents unsure about their choice of specialty

interest in the field of choice, their personal statement is ready to impress the interviewers, and they are well-prepared for the successful interview season. On the other hand, there’s a group of residents not able to determine the post-residency plan. Having gone through the experience of fellowship interviews recently, I now understand the dilemma of a candidate who is not sure about the career path after the residency training. Such a resident often ends up applying in multiple specialties in one (...) match cycle. On the day of the match, while everyone else is waiting to hear whether they matched or not and where they’ll be getting further training, this resident also awaits to know which specialty s/he is entering. I hear people saying that they’re capable of liking any specialty, but can you like, for example, nephrology when you always wanted to do critical care? You interviewed for nephrology just because you did not want to stay unmatched. For a resident unsure about the choice of specialty

2019 KevinMD blog

170. Standing on the shoulders of the basic science researchers who came before us

of topics — from his adventures in Stockholm, Sweden to his work-life balance — but his remarks on one particular subject stuck with me. It turns out that Dr. Lefkowitz, when interviewing candidates to work in his lab, prefers to work with those who attribute most of their successes to luck and he credits many of his own accomplishments to it as well. To say that doctors like control would be an understatement — we’re obsessed with it. We like to titrate our drugs carefully for our patients, down (...) steered by curiosity, researchers chasing knowledge for the sake of knowledge. And along the way, serendipity occasionally strikes. So while the allure of translational medicine is sexy and certainly more profitable, the basic scientists who ask the fundamental questions of human biology equally deserve our attention and funding. It’s a neglected side of medicine that is often overlooked by the public, the media, and even physicians. I admit that my primary motivation for dedicating a year to research

2019 KevinMD blog

171. The Koch Brothers and Vice President Mike Pence back a final push to pass the cruel sham known as “right-to-try”

as “progressive disease or medical or surgical condition that entails significant functional impairment, that is not considered by a treating physician to be reversible even with administration of current federal drug administration approved and available treatments, and that, without life-sustaining procedures, will soon result in death.” Various states define this condition in somewhat different ways, some with some room for interpretation. One of the most problematic passages, if not the most problematic (...) if there is any, and their care is still monitored by an institutional review board (IRB), with any adverse events recorded and considered by the FDA. Moreover, the FDA approves nearly all such requests (99%). In contrast, under right-to-try, there is no IRB oversight. It’s all between the company and the patient, a libertarian paradise! Right-to-try laws also limit what patients can do in the event of malpractice or negligence. All of them broadly immunize physicians advising or administering right-to-try

2018 Respectful Insolence

172. Whatever happened to Dr. Daniel Neides, a year after he was forced to leave the Cleveland Clinic because of his antivaccine rant?

once I arrived (letting the staff know, of course, that I am not waiting to see that doctor, and why.) Panacea I hear you. My Women’s Health rotation was full of functional medicine nonsense, and a lot of the patients were antivax. The physician who owned the practice wasn’t, but he was happy to enable some of this stuff, because a lot of his patients were cash only patients. Demodocus Worrisome indeed. Metrohealth’s a bit better, I think, but there’s still a crap load of breast is best and other (...) article from U.S. News and World Report): “Are animal fats all bad? Fat is where toxins tend to be stored in animals. Again, knowing the source of your food is important! So the inflammatory profile of fat from a conventionally raised animal living in crowded, filthy conditions being fed GMO corn feed is vastly different than fat from an organic pasture raised animal living with minimal stress.” Neides: “As a physician, I can appreciate how confusing nutritional recommendations can be. The important

2018 Respectful Insolence

173. Oprah Winfrey for President? Does anyone remember all the pseudoscience and quackery she’s promoted?

person because she has an ability to inspire, and make people feel like they want to be her friend. But I question how much she really even is that. If you saw her show in the later years, she was horrible at dealing with the guests who weren’t celebrities or hawking whatever New Age fad she was currently into. She’d interrupt them, talk about herself, look disinterested, and so on. There is one episode that stands out in my mind where she was interviewing grieving parents and kept repeating graphic (...) suppose if the choice were between Stalin or Hitler and nobody was running a viable write-in campaign then that might be a conundrum. However, it also should cause you to question whether you had done enough before the general election. Could you have, say, helped persuade a better candidate to run? Did you support a better candidate during the nomination process? Did you encourage people to nominate a better candidate? Did you participate in the primaries, caucuses, or conventions as appropriate

2018 Respectful Insolence

174. How minimally invasive surgery was spun as the ‘latest and greatest’ for cervical cancer

of a hospital’s nine-month-old robotic surgery system, deemed a “success” by one physician who advised: “Patients should be seeking out this surgery.” And a 2011 story in Carlisle, Pa.’s The Sentinel gave a woman’s glowing account of robot-assisted hysterectomy, which she said led to “so little pain” that she had to keep reminding herself she just had surgery. Those were among at least 20 one-sided newspaper stories that turned up in a ProQuest database search. Such channeling of provider hype partly explains (...) of gynecologic oncology and reproductive medicine at Houston’s University of Texas MD Anderson Cancer Center. “There has been a tremendous marketing of the minimally invasive approach, including physicians marketing the uniqueness of their practice, saying ‘I’m the only one who does this approach.’ When you set a level of uniqueness about what you do, then automatically patients will think it’s better,” Ramirez said. The trial — covered last week by , , , and others — showed three-year overall survival

2018 HealthNewsReview

175. What The New York Times didn’t say about a woman ‘caught in the crossfire’ between insurers and drugmakers

restrictions. (A appeared in an op/ed under the byline of a patient advocate with the Global Healthy Living Foundation, which is funded by Amgen, a maker of PCSK9 inhibitors.) FH advocates agree to with the foundation, including referring media inquiries to foundation staff. That raises questions about whether Ames is really a typical patient. Coached on messaging Further, readers deserve to know that there was a bit of grooming behind her industry-friendly message. In 2015 she wrote an impassioned (...) with the FH Foundation. “We hit the ground running with two days of interviews, science discussions, lessons on social media and brainstorms on how to raise FH awareness,” Ames says in the piece. It’s a safe bet that such training is performed by facilitators who are prone to put a rosy spin on products sold by the foundation’s primary sponsors. Those major sponsors include Amgen and Sanofi/Regeneron, which make the two PCSK9 inhibitors currently on the market; The Medicines Company, which has been

2018 HealthNewsReview

176. Patient Dignity (Formerly: Patient Modesty): Volume 93

and explain what their purpose is and why they are there and ask permission before they do anything. When patients need attention, the attendant would introduce themselves then escort the person back to a bay or room. Next, they would be respectfully asked to remove all their clothes and put on a johnny gown which would then be handed to them. The attendant would ask if they have any questions. If so, they would answer them to the best of their ability within facility rules. If no questions, the attendant (...) ways (like using male hospitals instead of female personnel), to take care of male related intimate issues if the patient wants same gender care. Whether one’s personal preference is for either same-gender or opposite-gender medical care, their choice should not only be respected by everyone, but also accommodated by all healthcare providers and their affiliates without question. The shot of humanity is something our healthcare system is in desperate need of right now so I hope, they will be wise

2019 Bioethics Discussion Blog

177. ASCO pumps up a one-sided view of lung cancer screening: Here’s what most of the coverage missed

be the result of a thorough discussion of the possible benefits, limitations, and known and uncertain harms.” It cited “substantial harms, most notably the risk for false-positive results and incidental findings that lead to a cascade of testing and treatment that may result in more harms, including the anxiety of living with a lesion that may be cancer.” A more balanced view The AP , mentioning “worries about false alarms and follow-up tests” high in the story and interviewing both patients who support (...) screening and experts who expressed doubts: But screening has a dark side: research shows that over three years of annual scans, 40 percent of people will have an abnormal finding that often leads to follow-up tests such as a lung biopsy, and complications of those can be fatal, said Dr. Otis Brawley, the American Cancer Society’s chief medical officer. “I’m committed to telling people the truth and letting people decide for themselves,” Brawley said, but added that if he were a candidate for screening

2018 HealthNewsReview

178. As renewed debate over health care reform begins to simmer in Washington, can journalists give the topic the attention it needs?

thought the government should play a larger role. Another said he wanted private health insurance companies out of the picture. But most voters approached for the article did not want to be interviewed, saying they didn’t understand the issue. Paul Her of Sacramento summed up their predicament: “I just don’t know enough.” If reporters in Colorado, Illinois, or Virginia asked the same question, no doubt they’d get the same answers. To most Americans, what a new kind of health care system would look (...) conditions. A before the November election found 75% of Americans said it was “very important” that protections for preexisting conditions and ensuring guaranteed coverage remain. The fact that so many candidates, including Republicans, commercials citing their bona fides when it came to preexisting conditions reinforced the potency of that issue among voters. While further reform will be challenging given the current political climate, serious consideration of the issue is taking root as a wave of new

2018 HealthNewsReview

179. Ten years of multidisciplinary teams meetings in oncology: current situation and perspectives

. KCE Reports 239Cs. D/2015/10.273/21. This document is available on the website of the Belgian Health Care Knowledge Centre. KCE Report 239 MDT meetings in oncology 1 ? TABLE OF CONTENTS LIST OF FIGURES 5 LIST OF TABLES 7 LIST OF ABBREVIATIONS 9 ? SCIENTIFIC REPORT 10 1 INTRODUCTION, OBJECTIVE AND RESEARCH QUESTIONS 10 1.1 INTRODUCTION 10 1.2 OBJECTIVES AND RESEARCH QUESTIONS 11 1.3 STRUCTURE OF THIS REPORT 11 2 BACKGROUND INFORMATION 12 2.1 THE BELGIAN CONTEXT 12 2.1.1 Evolution of billing codes (...) to the hospital/site and external) (N=1 014) 68 Figure 25 – Clinical stage defined (N=975) 70 Figure 26 – Pathological stage defined (N=978) 71 Figure 27 – Recommendations used to guide the treatment strategy during the last MDT meeting (N=1 014) 72 Figure 28 – The utility of the guidelines during the last MDT meeting according to physicians (N=839) 72 Figure 29 – Check of the adherence of the decision to the oncological handbook (N=25) 73 Figure 30 – Support during last MDT meeting (N=1 014) 74 Figure 31

2015 Belgian Health Care Knowledge Centre

180. Prostate Cancer, Nutrition, and Dietary Supplements (PDQ®): Health Professional Version

, they do not all disclose their CAM use to treating According to results from the PCATS study, 43% of patients discussed their CAM use with a healthcare professional.[ ] In two separate studies, 58% of respondents told their doctors about their CAM usage.[ , ] How do prostate cancer patients decide whether or not to use CAM? A qualitative study published in 2005 described results from interviews with prostate cancer patients. The study identified differences in thinking patterns between CAM users

2017 PDQ - NCI's Comprehensive Cancer Database

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>